P-309 Low/intermerdiate-1 risk MDS treated with high-dose rHu-EPO: Hematological responses and impact on quality of life, a prospective GFM study. - Tessoulin, B.; Beyne-RAuzy, O.; Guerci, A.; Gyan, E.; Hunault, M.; Ianotto, J.C.; Shanti, A.; Stamatoullas, A.; Dreyfus, F.; Fenaux, P.; Delaunay, J. (Leukemia Research, 2013)